Join Chris Walsh, CEO at Acadia as he discusses how the OTC Derivatives industry is mainstreaming UMR compliance and starting to move towards optimizing their performance. Chris shares his insights on how the industry is adapting to a more holistic approach to risk, margin and collateral -coining the phrase Optimal Margin Management.
Recorded and produced by Lansons
Listen time – 13 minutes
John Pucciarelli, Head of Industry and Regulatory Strategy and Stuart Smith, Co-Head of Business Development at Acadia spend time in the studio discussing the...
In this insightful episode, John Pucciarelli and Stuart Smith dive into two pivotal regulatory developments shaping the financial landscape. They explore recent guidance from...
Join Acadia’s CEO Chris Walsh, Co-Head of Quantitative Services Roland Lichters, and Partner Scott Sobolewski as they sit down to dig deeper into the...